Cortex Pharmaceuticals, Inc. – Trademark Portfolio

Entity Type: 03

Cortex Pharmaceuticals, Inc. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 9 filings in this category. Currently, 1 trademark is registered. Notable registered marks include AMPAKINE. The owner is based in Irvine, CA.

15241 Barranca Parkway

Irvine, CA 92618

9 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

AMPAKINE
AMPAKINE
Abandoned 2010
AMPALEX
AMPALEX
Abandoned 2008
CORTEX
CORTEX
Cancelled 1998
CORTEX
CORTEX
Cancelled 1998
VASOLEX
VASOLEX
Abandoned 1993
AMPALEX
AMPALEX
Cancelled 1993
AMPAKINE
AMPAKINE
Registered 1993
RESTENEX
RESTENEX
Abandoned 1993

Trademark Classifications

Cortex Pharmaceuticals, Inc.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (9 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Cortex Pharmaceuticals, Inc. have?

Cortex Pharmaceuticals, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 1 registered, 4 abandoned, 4 cancelled.

What trademark classes does Cortex Pharmaceuticals, Inc. file in?

Cortex Pharmaceuticals, Inc. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Cortex Pharmaceuticals, Inc.'s most well-known trademarks?

Cortex Pharmaceuticals, Inc.'s registered trademark portfolio includes well-known marks such as AMPAKINE. These are among 1 currently registered trademark in the portfolio.

What is Cortex Pharmaceuticals, Inc.'s trademark registration success rate?

Cortex Pharmaceuticals, Inc. has a 11% trademark registration rate, with 1 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.